Skip to search formSkip to main contentSkip to account menu

Lutathera

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
SAT-LB311 Inoperable, Metastatic Pheochromocytoma & Paraganglioma Tumor Size Reduction After Lu-177-dotatate (Lutathera®) Treatment Trial: The Role of Nursing
Abstract Tumor Size Reduction after Lu-177-DOTATATE (Lutathera®) Treatment in Patients with Inoperable Metastatic… 
2020
2020
MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
Abstract Background: Lutetium-177 (177Lu) DOTATATE (Lutathera ®) is a form of peptide receptor radionuclide therapy (PRRT) that… 
2019
2019
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
2018
2018
First edible cottonseed go-ahead
particles. But instead of yttrium-90, Lutathera uses lutetium-177, a lower energy isotope that avoids some of the collateral… 
2018
2018
60 Comparison of organ-based absorbed doses estimations by using PLANET®Dose and OLINDA/EXM V2.0 in patients with peptide receptor radionuclide therapy (PRRT) treated with Lutathera®
2018
2018
FDA Approves Lutathera for Gastroenteropancreatic Neuroendocrine Tumors
The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor… 
2017
2017
Neuroendokrine Tumore (NET) des Gastrointestinaltraktes: Nuklearmedizinische Optionen in Diagnose und Therapie // Neuroendocrine Tumours (NET) of the Gastrointestinal Tract: Nuclear Medicine Methods…
Neuroendocrine Tumours (NET) of the Gastrointestinal Tract: Nuclear Medicine Methods in Diagnosis and Therapy. In the diagnosis… 
2016
2016
SP-0572: Role and validation of deformable image registration in clinical practice
2016
2016
Lutathera Slows Disease Progression in Midgut Neuroendocrine Tumors
A novel drug, 177Lutetium-DOTATATE (Lutathera), significantly lowered the risk for disease progression or death among patients… 
2015
2015
Lutathera Delayed Progression of Midgut Neuroendocrine Tumors
Patients with midgut neuroendocrine tumors had significantly delayed disease progression when treated with Lutathera compared… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)